Soluble amyloid precursor protein β as blood-based biomarker of Alzheimer's disease

[1]  L. Provinciali,et al.  Platelet Amyloid Precursor Protein Isoform Expression in Alzheimer's Disease: Evidence for Peripheral Marker , 2011, International journal of immunopathology and pharmacology.

[2]  R. Faber,et al.  Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. , 1999, Neurology.

[3]  Y. Qian,et al.  Enhanced production of amyloid precursor protein mRNA by peripheral mononuclear blood cell in Alzheimer's disease , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[4]  E. Reiman,et al.  Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias , 2008, Journal of Nuclear Medicine.

[5]  W. M. van der Flier,et al.  Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort , 2012, Neurology.

[6]  F. Jessen,et al.  Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study , 2010, Molecular Psychiatry.

[7]  Hans Förstl,et al.  CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease , 2011, Neurology.

[8]  R. Mayeux,et al.  Meta-analysis of plasma amyloid-β levels in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[9]  Huaxi Xu,et al.  Proteolytic processing of Alzheimer’s β‐amyloid precursor protein , 2012, Journal of neurochemistry.

[10]  A. Simon,et al.  Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex , 2011, Journal of neuroscience research.